Publications by authors named "Nancy Pryer"

Claim this Profile
P
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies.
Qing Sheng, Joseph A D'Alessio, Daniel L Menezes, Christopher Karim, Yan Tang, Nancy K Pryer

Mol Cancer Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
Yuanbin Ru, Carley Corado, Russell K Soon, Andrew C Melton, Adam Harris, Nancy Pryer

Ann Clin Transl Neurol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.
Tinya Abrams, Anu Connor, Christie Fanton, Steven B Cohen, Thomas Huber, Nancy Pryer

Clin Cancer Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
Hui Gao, Joshua M Korn, Stéphane Ferretti, John E Monahan, Youzhen Wang, Nancy K Pryer

Nat Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, structure-activity relationship, and in vivo characterization of the development candidate NVP-HSP990.
Christopher M McBride, Barry Levine, Yi Xia, Cornelia Bellamacina, Timothy Machajewski, Nancy Pryer

J Med Chem· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.
Brian Ruffell, Debbie Chang-Strachan, Vivien Chan, Alexander Rosenbusch, Christine M T Ho, Nancy Pryer

Cancer Cell· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
Matthew Holderfield, Edward Lorenzana, Ben Weisburd, Lisa Lomovasky, Lise Boussemart, Nancy Pryer

Cancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mouse tumour models to guide drug development and identify resistance mechanisms.
Meghna Das Thakur, Nancy K Pryer, Mallika Singh

J Pathol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells.
Debbie C Strachan, Brian Ruffell, Yoko Oei, Mina J Bissell, Lisa M Coussens, Nancy Pryer

Oncoimmunology· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Meghna Das Thakur, Fernando Salangsang, Allison S Landman, William R Sellers, Nancy K Pryer

Nature· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
Daniel L Menezes, Pietro Taverna, Michael R Jensen, Tinya Abrams, Darrin Stuart, Nancy K Pryer

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo.
Deryk Loo, Nancy Pryer, Peter Young, Tony Liang, Suzanne Coberly

Mol Cancer Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xiaohua Xin, Tinya J Abrams, Paul W Hollenbach, Katherine G Rendahl, Yan Tang, Nancy K Pryer

Clin Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
David W Fry, Patricia J Harvey, Paul R Keller, William L Elliott, Maryanne Meade, Nancy K Pryer

Mol Cancer Ther· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Lesley J Murray, Tinya J Abrams, Kelly R Long, Theresa J Ngai, Lisa M Olson, Nancy K Pryer

Clin Exp Metastasis· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Nancy K Pryer, Leslie B Lee, Regina Zadovaskaya, Xiaoming Yu, Juthamas Sukbuntherng

Clin Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Tinya J Abrams, Lesley J Murray, Enrico Pesenti, Vicky Walker Holway, Tina Colombo, Nancy K Pryer

Mol Cancer Ther· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Tinya J Abrams, Leslie B Lee, Lesley J Murray, Nancy K Pryer, Julie M Cherrington

Mol Cancer Ther· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis